Huanglian-Renshen-Decoction Maintains Islet β-Cell Identity in T2DM Mice through Regulating GLP-1 and GLP-1R in Both Islet and Intestine.
10.1007/s11655-024-3915-1
- Author:
Wen-Bin WU
1
;
Fan GAO
1
;
Yue-Heng TANG
1
;
Hong-Zhan WANG
1
;
Hui DONG
2
;
Fu-Er LU
2
;
Fen YUAN
3
Author Information
1. Institution of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
2. Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
3. Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. echo_yf@tjh.tjmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Huanglian-Renshen-Decoction;
glucagon-like peptide-1;
glucagon-like peptide-1 receptor;
islet β cell;
type 2 diabetes mellitus
- MeSH:
Animals;
Glucagon-Like Peptide 1/metabolism*;
Diabetes Mellitus, Type 2/metabolism*;
Glucagon-Like Peptide-1 Receptor/metabolism*;
Insulin-Secreting Cells/pathology*;
Drugs, Chinese Herbal/pharmacology*;
Male;
Blood Glucose/metabolism*;
Insulin/blood*;
Mice;
Intestinal Mucosa/pathology*;
Apoptosis/drug effects*;
Cell Proliferation/drug effects*;
Islets of Langerhans/pathology*
- From:
Chinese journal of integrative medicine
2025;31(1):39-48
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To elucidate the effect of Huanglian-Renshen-Decoction (HRD) on ameliorating type 2 diabetes mellitus by maintaining islet β -cell identity through regulating paracrine and endocrine glucagon-like peptide-1 (GLP-1)/GLP-1 receptor (GLP-1R) in both islet and intestine.
METHODS:The db/db mice were divided into the model (distilled water), low-dose HRD (LHRD, 3 g/kg), high-dose HRD (HHRD, 6 g/kg), and liraglutide (400 µ g/kg) groups using a random number table, 8 mice in each group. The db/m mice were used as the control group (n=8, distilled water). The entire treatment of mice lasted for 6 weeks. Blood insulin, glucose, and GLP-1 levels were quantified using enzyme-linked immunosorbent assay kits. The proliferation and apoptosis factors of islet cells were determined by immunohistochemistry (IHC) and immunofluorescence (IF) staining. Then, GLP-1, GLP-1R, prohormone convertase 1/3 (PC1/3), PC2, v-maf musculoaponeurotic fibrosarcoma oncogene homologue A (MafA), and pancreatic and duodenal homeobox 1 (PDX1) were detected by Western blot, IHC, IF, and real-time quantitative polymerase chain reaction, respectively.
RESULTS:HRD reduced the weight and blood glucose of the db/db mice, and improved insulin sensitivity at the same time (P<0.05 or P<0.01). HRD also promoted mice to secrete more insulin and less glucagon (P<0.05 or P<0.01). Moreover, it also increased the number of islet β cell and decreased islet α cell mass (P<0.01). After HRD treatment, the levels of GLP-1, GLP-1R, PC1/3, PC2, MafA, and PDX1 in the pancreas and intestine significantly increased (P<0.05 or P<0.01).
CONCLUSION:HRD can maintain the normal function and identity of islet β cell, and the underlying mechanism is related to promoting the paracrine and endocrine activation of GLP-1 in pancreas and intestine.
